Gapping down
In reaction to disappointing earnings/guidance:
- TLRD -25.5%, ACB -10.2%, OXM -8.1%, LSTR -5.2%, ORCL -1.4%, T -0.6% (recaps comments made today at the Bank of America Merrill Lynch Media, Communications & Entertainment conference)
Other news:
- TOCA -82.5% (reports results of Toca 5 Phase 3 trial in recurrent brain cancer -- missed primary and all secondary endpoints)
- ADVM -35.2% (presents positive 24-week clinical data from the first cohort of patients treated with a one-time intravitreal dose of ADVM-022 in the OPTIC phase 1 clinical trial in wet age-related macular degeneration)
- CELH -12.5% (to acquire Nordic wellness company Func Food Group Oyj - expected to close in October 2019; launches public offering of shares of common stock)
- CPRX -11.2% (announces public offering of 8.0 mln shares of common stock)
- AVYA -8.3% (headlines the company will pursue a possible venture with RingCentral (RNG) instead of a sale)
- DXC -6% (elected Mike Salvino as President and Chief Executive Officer, effective today)
- HSKA -4.5% (proposes to offer $75.0 mln of convertible senior notes due 2026)
- APLS -4.3% (announces intention to offer $200 mln of convertible senior notes due 2026)
- FATE -2.1% (prices 8.6 mln shares of common stock at $17.50 per share)
- RDY -1.8% (lower as local news sources are reporting fire and HAZMAT situation at Dr. Reddy's Laboratory in Middleburgh)
- BHGE -1.8% (prices secondary offering of 115 million shares of BHGE Class A common stock by General Electric (GE) a price to the public of $21.50 per share)
- BEST -1.5% (proposes offering of up to US$175 mln in aggregate principal amount of convertible senior notes due 2024)
- MRNA -1.1% (announces positive data from three-month interim analysis of safety and immunogenicity of the Phase 1 study of its investigational cytomegalovirus vaccine)
Analyst comments:
- N/A.